

Anti-IL23 α (Mirikizumab), Humanized Antibody

07/20

CATALOG NO.: A2174-100 (100 μ g)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of IL-23 but does not bind to IL12. IL-23 is expressed and secreted by dendritic cells and macrophages. It belongs to the family of IL-12 cytokines and has two subunits: p40 that is shared with IL-12 and p19 that is unique for IL-23. IL-23 plays a critical role in maintaining and expanding Th17 cells. It also stimulates multiple innate immune cells such as myeloid cells and NK cells to produce proinflammatory cytokines that play an important role in the pathogenesis of inflammatory diseases such as Ulcerative Colitis (UC). By binding to the p19 subunit of IL-23, the antibody inhibits the release of proinflammatory cytokines and reduces the inflammatory response. The original drug is currently undergoing clinical trials to treat moderate-to-severe UC, psoriasis, and Crohn's disease.

ALTERNATE NAMES: LY-3074828, LY3074828, P19, SGRF, IL-23, IL23A, IL23P19

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human IL23 α

CAS NUMBER: 1884201-71-1

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)
 Anti-IL-17 α (Ixekizumab), Humanized Antibody (A2149)
 Anti-IL-12 β (Ustekinumab), Human IgG1 Antibody (A2137)
 Anti-IL-23 α (Guselkumab), Human IgG1 Antibody (A2147)
 Anti-IL-23 α (Tildrakizumab), Humanized Antibody (A2159)

FOR RESEARCH USE ONLY! Not to be used on humans.